174 related articles for article (PubMed ID: 31519379)
21. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
22. Preoperative Evaluation of Sellar and Parasellar Macrolesions by [
Tosaka M; Higuchi T; Horiguchi K; Osawa T; Arisaka Y; Fujita H; Tsushima Y; Yoshimoto Y
World Neurosurg; 2017 Jul; 103():591-599. PubMed ID: 28427982
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
24. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
25. Technetium-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitary adenomas.
Lastoria S; Colao A; Vergara E; Ferone D; Varrella P; Merola B; Lombardi G; Salvatore M
Eur J Endocrinol; 1995 Jul; 133(1):38-47. PubMed ID: 7627336
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
27. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
28. [Established nuclear medicine techniques for tumour diagnosis (tumour SPECT): can they still compete with (18)F-FDG-PET?].
Schmidt M; Eschner W; Dietlein M; Theissen P; Schicha H
Nuklearmedizin; 2005 Feb; 44(1):37-48; quiz N2-3. PubMed ID: 15711728
[TBL] [Abstract][Full Text] [Related]
29. CRH stimulation improves
Boyle J; Patronas NJ; Smirniotopoulos J; Herscovitch P; Dieckman W; Millo C; Maric D; Chatain GP; Hayes CP; Benzo S; Scott G; Edwards N; Ray Chaudhury A; Lodish MB; Sharma S; Nieman LK; Stratakis CA; Lonser RR; Chittiboina P
Endocrine; 2019 Jul; 65(1):155-165. PubMed ID: 31062234
[TBL] [Abstract][Full Text] [Related]
30. All that glitters on PET is not cancer! 18F-deoxy-glucose avidity versus tumor biology: pituitary incidentaloma in a survivor of two previous unrelated malignancies.
Miljić D; Manojlović-Gačić E; Skender-Gazibara M; Milojević T; Bogosavljević V; Kozarević N; Petrović N; Stojanović M; Pekić S; Doknić M; Petakov M; Popović V
Endokrynol Pol; 2017; 68(3):352-359. PubMed ID: 28660992
[TBL] [Abstract][Full Text] [Related]
31. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.
de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT
Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241
[TBL] [Abstract][Full Text] [Related]
32. Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria.
Hyun SH; Choi JY; Lee KH; Choe YS; Kim BT
J Nucl Med; 2011 Apr; 52(4):547-50. PubMed ID: 21421711
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic imaging of dopamine receptors in pituitary adenomas.
de Herder WW; Reijs AEM; Feelders RA; van Aken MO; Krenning EP; van der Lely AJ; Kwekkeboom DJ
Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S53-S56. PubMed ID: 17413189
[TBL] [Abstract][Full Text] [Related]
34. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
de Herder WW; Reijs AE; de Swart J; Kaandorp Y; Lamberts SW; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
[TBL] [Abstract][Full Text] [Related]
35. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
36. Is technetium-99m-MIBI taken up by the normal pituitary gland? A comparison of normal pituitary glands and pituitary adenomas.
Kojima T; Mizumura S; Kumita SI; Kumazaki T; Teramoto A
Ann Nucl Med; 2001 Aug; 15(4):321-7. PubMed ID: 11577756
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
[TBL] [Abstract][Full Text] [Related]
38. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
39. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
[TBL] [Abstract][Full Text] [Related]
40. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
